7 results
To establish the safety, tolerability, and early efficacy of multiple doses of hLF1-11 given once daily for 14 days.
The study objective is to measure beta cell mass and function in subjects with type 1 diabetes during and shortly after the honeymoon phase, to determine whether the change in metabolic control is mainly caused by a decrease in the total number of…
The main study objective is to measure residual beta cell mass, indicated by the pancreatic uptake of Ga-68-exendin using quantitative PET, in type 1 diabetes patients with stable near-normal and unstable glucose control, to improve understanding of…
The purpose of this study is to investigate how quickly and to what extent rogaratinib is absorbed, distributed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics). Rogaratinib will be labelled with 14 Carbon (…
The primary objective of the entire study is to compare rogaratinib (BAY1163877) with chemotherapy (docetaxel, paclitaxel or vinflunine) in terms of prolonging the Overall survival (OS) of patients with FGFR positive urothelial carcinoma.
The primairy objective of this study is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes after FMT. Within 1 month…
The study objective is to compare the pituitary uptake of 68Ga-NODAGA-exendin in patients with and without adequate response (based on HbA1c or weight loss or classification by the treating diabetologist) to GLP-1R agonist treatment, to increase…